Literature DB >> 1685091

The influence of food on the oral bioavailability of terazosin.

J J McNeil, O H Drummer, K Raymond, E L Conway, W J Louis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1685091      PMCID: PMC1368564     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  Terazosin (Hytrin): cumulative experience of clinical trials in the USA for the treatment of mild to moderate essential hypertension.

Authors:  J L Pool; E B Nelson; A A Taylor; J R Mitchell
Journal:  Br J Clin Pract Suppl       Date:  1987-12

2.  Effect of age on pharmacokinetics of and blood pressure responses to prazosin and terazosin.

Authors:  J J McNeil; O H Drummer; E L Conway; B S Workman; W J Louis
Journal:  J Cardiovasc Pharmacol       Date:  1987-08       Impact factor: 3.105

Review 3.  Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia.

Authors:  H Lepor
Journal:  Prostate Suppl       Date:  1990

4.  Pharmacokinetics of prazosin in normotensive subjects after low oral doses.

Authors:  M K Dynon; B Jarrott; O Drummer; W J Louis
Journal:  Clin Pharmacokinet       Date:  1980 Nov-Dec       Impact factor: 6.447

5.  Pharmacokinetics of terazosin.

Authors:  R C Sonders
Journal:  Am J Med       Date:  1986-05-23       Impact factor: 4.965

6.  Rest and exercise cardiovascular effects of terazosin in congestive heart failure.

Authors:  R D Magorien; S Sinnathamby; C V Leier; H Boudoulas; D V Unverferth
Journal:  Am J Cardiol       Date:  1990-03-01       Impact factor: 2.778

  6 in total
  1 in total

Review 1.  Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.